ARK Genomic Revolution ETF (ARKG) ETF Analysis

Fund Overview

ARK Genomic Revolution ETF trades as ARKG and is categorised as Health. The fund holds $2.02B in total net assets. The expense ratio is 0.75%. On a $10,000 position that is $75.00 a year. ARK ETF Trust is the fund family on file. It has been trading since October 31, 2014.

The largest positions on file are Tempus AI Inc Class A common stock (TEM), CRISPR Therapeutics AG (CRSP), and Twist Bioscience Corp (TWST). Tempus AI Inc Class A common stock alone accounts for 8.62% of the portfolio. The ten largest positions together make up 58.96% of the fund.

Performance Analysis

ARKG last closed at $47.14 on September 4, 2026. The trailing one-year price return is +89.32%. The stored price history starts on February 7, 2025, and the total return since then is +74.66%. The provider also reports a 3 years average return of +13.12%.

2026 is still running; the price is +62.72% year to date.

Price & Risk Profile

Annualized volatility over the trailing 1 year is 44.82%. The reported beta is 2.37. The 52-week range on file runs from $24.60 to $50.54. The latest close sits 91.63% above that 52-week low. The volatility figure is calculated from the stored daily closes, the same series the charts on this page use.